Watanabe Y, Shimizu J, Hashizume Y, Tsunamura Y, Yamada T, Iwa T, Sakai S, Murayama T, Koshimura S, Saito M
Department of Surgery, Kanazawa University School of Medicine, Japan.
Biotherapy. 1990;2(3):235-45. doi: 10.1007/BF02173525.
We have studied the immunological status of patients treated with streptococcal preparation OK-432. Two KE of OK-432 was injected intramuscularly once every week for more than three years unless the patients died. The natural killer (NK) activity in those patients who underwent curative surgery for lung cancer and had no sign of recurrence was significantly increased (P less than 0.01) during the OK-432 treatment. However, the NK activity in the patients who had persistent disease (non-resected cases, incompletely resected cases or recurrent cases) was not significantly increased in comparison with that before the immunotherapy. Also, in the cases with no clinical symptoms of recurrence, both the lymphoblastogenetic reactions to the mitogens and the IL-2 production were significantly enhanced (P less than 0.01) during the administration of OK-432. Reactions in the SU-PS (polysaccharide taken from the cell-wall fraction of the Streptococcus pyogenes SU strain and containing 7.2% of protein) skin-test appeared to significantly correlate with the immunological status of the patients under OK-432 therapy, but the PHA and PPD skin reactions showed no definitive enhancement. The survival rate of the patients whose SU-PS skin tests were positive during the OK-432 immunotherapy was significantly higher (P less than 0.01) than that of the patients with negative reactions.
我们研究了用链球菌制剂OK-432治疗的患者的免疫状态。除非患者死亡，否则每周一次肌肉注射2KE的OK-432，持续三年以上。在OK-432治疗期间，那些接受了肺癌根治性手术且无复发迹象的患者的自然杀伤（NK）活性显著增加（P<0.01）。然而，与免疫治疗前相比，患有持续性疾病（未切除病例、切除不完全病例或复发病例）的患者的NK活性没有显著增加。此外，在没有复发临床症状的病例中，在给予OK-432期间，对有丝分裂原的淋巴细胞生成反应和IL-2产生均显著增强（P<0.01）。SU-PS（从化脓性链球菌SU菌株的细胞壁部分提取的多糖，含7.2%的蛋白质）皮肤试验中的反应似乎与接受OK-432治疗的患者的免疫状态显著相关，但PHA和PPD皮肤反应没有明显增强。在OK-432免疫治疗期间SU-PS皮肤试验呈阳性的患者的生存率显著高于（P<0.01）反应阴性的患者。
